Salvianolic Acid B Alleviates Atrial Fibrillation–Associated Fibrosis With Modulation of COL1A2 and the PI3K‐AKT Pathway
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/5515602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Pengran Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China, hebmu.edu.cn. Hauptthemen laut MEDLINE: Benzofurans, Proto-Oncogene Proteins c-akt, Atrial Fibrillation, Myocytes, Cardiac. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science Research Project of Hebei.
Abstract (Originalsprache)
Background
Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is strongly associated with atrial fibrosis. Salvianolic acid B (Sal‐B), a bioactive compound extracted from Salvia miltiorrhiza , demonstrates cardioprotective properties, though its specific role in AF remains to be elucidated.
Methods
Transcriptome analysis of the GSE115574 dataset was performed to identify COL1A2 as a differentially expressed gene in patients with AF. Molecular docking simulations were performed to evaluate the binding affinity between Sal‐B and COL1A2. For in vitro experiments, an injury model was established in AC16 cardiomyocytes using Angiotensin II (Ang‐II) treatment, followed by intervention with either Sal‐B (80 μ g/mL) or COL1A2 siRNA. Cellular viability, apoptosis, migration capacity, and fibrosis markers (COL1A1, α ‐SMA, and collagen III) were subsequently assessed. In vivo studies employed an ACh‐CaCl 2 –induced AF rat model, with cardiac function evaluated through electrocardiography (ECG) and echocardiography. Myocardial tissue damage was examined via hematoxylin–eosin (HE) staining and Masson′s trichrome staining. Western blot analysis was used to determine COL1A2 expression and PI3K‐AKT pathway activity.
Results
COL1A2 expression was significantly upregulated in AF, and molecular docking demonstrated its strong binding affinity for Sal‐B. Sal‐B treatment rescued Ang‐II–induced cardiomyocyte damage, reduced apoptosis, and suppressed fibrosis marker expression. In rat models, either Sal‐B or si‐ COL1A2 alone shortened the AF duration, improved cardiac function (attenuated the elevated E / E ′ ratio while restoring the ejection fraction), and reduced fibrosis and inflammation. The combined treatment synergistically restored sinus rhythm and normalized collagen deposition, suggesting a modulatory role of Sal‐B in these processes.
Conclusions
Sal‐B alleviates AF in association with COL1A2 modulation and PI3K‐AKT signaling pathway inhibition, which may contribute to reducing atrial fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China, hebmu.edu.cn.
- Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn.
- Emergency Department, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn.
ORCID-Profile: Pengran Wang, Jianhua Ma, Jianlong Li, Shanshan Li, Yeran Zhu, Ruibin Li, Jidong Zhang
Förderung
- Medical Science Research Project of Hebei
Zitieren
APA
Wang, P., Ma, J., Li, J., Li, S., Zhu, Y., Li, R., & Zhang, J. (2026). Salvianolic Acid B Alleviates Atrial Fibrillation–Associated Fibrosis With Modulation of COL1A2 and the PI3K‐AKT Pathway. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/5515602
Vancouver
Wang P, Ma J, Li J, Li S, Zhu Y, Li R, et al. Salvianolic Acid B Alleviates Atrial Fibrillation–Associated Fibrosis With Modulation of COL1A2 and the PI3K‐AKT Pathway. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/5515602
BibTeX
@article{Wang2026,
author = {Wang, Pengran and Ma, Jianhua and Li, Jianlong and Li, Shanshan and Zhu, Yeran and Li, Ruibin and Zhang, Jidong},
title = {Salvianolic Acid B Alleviates Atrial Fibrillation–Associated Fibrosis With Modulation of COL1A2 and the PI3K‐AKT Pathway},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/5515602}
}
EUVIMED